ArticleScientific reports2015
Microbiota prevents cholesterol loss from the body by regulating host gene expression in mice.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 53 citations in OpenAlex.
- Traditional Chinese medicine-based modulation of gut microbiota in coronary heart disease: probiotic synergy and translational perspectives.Frontiers in cardiovascular medicine · 2026Review
- Vitamin D and the aging skin: insights into oxidative stress, inflammation, and barrier function.Immunity & ageing : I & A · 2025Review
- Interactions between gut microbiota and cardiovascular drugs: effects on drug therapeutic effect and side effect.Frontiers in cardiovascular medicine · 2025Review
- Non-Pharmacological Therapeutic Options for the Treatment of Alzheimer's Disease.International journal of molecular sciences · 2022Review
- Characterization of interactions of dietary cholesterol with the murine and human gut microbiome.Nature microbiology · 2022Article
- Lactobacillus rhamnosus GG Promotes Intestinal Vitamin D Absorption by Upregulating Vitamin D Transporters in Senile Osteoporosis.Calcified tissue international · 2022Article
- Novel strategies to improve chicken performance and welfare by unveiling host-microbiota interactions through hologenomics.Frontiers in physiology · 2022Article
- Article
- Sitosterolemia: Twenty Years of Discovery of the Function ofInternational journal of molecular sciences · 2021Review
- Distinctive Gut Microbiota in Patients with Overweight and Obesity with Dyslipidemia and its Responses to Long-term Orlistat and Ezetimibe Intervention: A Randomized Controlled Open-label Trial.Frontiers in pharmacology · 2021Article
- Supplementation of Bacillus sp. DU-106 reduces hypercholesterolemia and ameliorates gut dysbiosis in high-fat diet rats.Applied microbiology and biotechnology · 2021Article
- Ezetimibe promotes CYP7A1 and modulates PPARs as a compensatory mechanism in LDL receptor-deficient hamsters.Lipids in health and disease · 2020Article
- Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2020Review
- Unraveling Host-Gut Microbiota Dialogue and Its Impact on Cholesterol Levels.Frontiers in pharmacology · 2020Review
- The intestinal microbiota regulates host cholesterol homeostasis.BMC biology · 2019Article
- Hematopoietic Npc1 mutation shifts gut microbiota composition in LdlrScientific reports · 2019Article
- Depletion of Gram-Positive Bacteria Impacts Hepatic Biological Functions During the Light Phase.International journal of molecular sciences · 2019Article
- Microbial impact on cholesterol and bile acid metabolism: current status and future prospects.Journal of lipid research · 2019Review
- Dietary Effects on Microbiota-New Trends with Gluten-Free or Paleo Diet.Medical sciences (Basel, Switzerland) · 2018Review
- Validation of control genes and a standardised protocol for quantifying gene expression in the livers of C57BL/6 and ApoE-/- mice.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
Abstract
We have previously observed that knockout of Niemann-Pick C1-Like 1 (NPC1L1), a cholesterol transporter essential for intestinal cholesterol absorption, reduces the output of dry stool in mice. As the food intake remains unaltered in NPC1L1-knockout (L1-KO) mice, we hypothesized that NPC1L1 deficiency may alter the gut microbiome to reduce stool output. Consistently, here we demonstrate that the phyla of fecal microbiota differ substantially between L1-KO mice and their wild-type controls. Germ-free (GF) mice have reduced stool output. Inhibition of NPC1L1 by its inhibitor ezetimibe reduces stool output in specific pathogen-free (SPF), but not GF mice. In addition, we show that GF versus SPF mice have reduced intestinal absorption and increased fecal excretion of cholesterol, particularly after treatment with ezetimibe. This negative balance of cholesterol in GF mice is associated with reduced plasma and hepatic cholesterol, and likely caused by reduced expression of NPC1L1 and increased expression of ABCG5 and ABCG8 in small intestine. Expression levels of other genes in intestine and liver largely reflect a state of cholesterol depletion and a decrease in intestinal sensing of bile acids. Altogether, our findings reveal a broad role of microbiota in regulating whole-body cholesterol homeostasis and its response to a cholesterol-lowering drug, ezetimibe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.